[144] KESTRA MEDICAL TECHNOLOGIES, LTD. SEC Filing
Kestra Medical Technologies notice of proposed resale: a reporting holder filed a Rule 144 notice to sell 15,000 restricted common shares granted under the issuer's equity compensation plan on 01/21/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies notice of proposed resale: a reporting holder filed a Rule 144 notice to sell 15,000 restricted common shares granted under the issuer's equity compensation plan on 01/21/2026. The filing lists three prior sales by the same holder: 15,000 shares on 02/17/2026 for $384,020.06, 15,000 shares on 03/17/2026 for $304,123.49, and 15,000 shares on 04/15/2026 for $300,671.04.
Insights
Rule 144 notice filed for resale of restricted shares; prior open-market sales recorded.
The filing records a 15,000-share restricted issuance dated 01/21/2026 under the company's equity compensation plan and a Rule 144 notice to sell that allotment. It also documents three prior sales by the same holder in 02/2026, 03/2026, and 04/2026 with explicit sale proceeds.
Timing and exact resale mechanics beyond the listed dates are not stated in the excerpt; cash‑flow treatment and broker involvement are shown only by the broker address line. Subsequent filings may disclose completion details.
AI-generated analysis. How Rhea-AI works. Not financial advice.